Pharma news
Americas
AstraZeneca unit and Samsung Bioepis resolve their patent dispute over a biosimilar | Settlement follows FDA approval for the generic drug in July 2024 | Agreement dismisses ongoing litigation and appeals, including a federal lawsuit and related patent reviews. 5 September 2024
Americas
Regeneron accused the Swiss pharma company of infringing a slew of patents related to Eylea and violating the BPCIA | Suit alleges that Sandoz failed to provide critical information during the approval process for its newly FDA-approved biosimilar | Sandoz “forced” Regeneron to guess which patents might be infringed. 29 August 2024
Americas
Biopharma firm sues CSPC for allegedly infringing Onivyde patent issued in August | Suit follows complaint in April asserting eight patents against Conjupro’s product. 27 August 2024
Americas
AstraZeneca successfully argued that “no reasonable jury” could find it had infringed the patents-in-suit claiming lung cancer patents | Reprieve comes after misconduct allegations against a Pfizer unit fell flat earlier this month. 15 August 2024
Pharma
Delaware judge denies pharma giant’s request for injunction on rivals’ generic of Entresto | Novartis ‘unlikely to succeed’ in proving infringement | Lawsuit is one of several attempts to preserve exclusivity of the drug ahead of patent expiry and US price caps. 13 August 2024
Americas
A Delaware jury found AstraZeneca liable for induced infringement of a cancer treatment in May | Pharma company levelled allegations of "unclean hands" and "patent misuse" at Pfizer unit. 8 August 2024
Americas
Big pharma subsidiary and Japanese collaborator allege infringement of blockbuster drug product | $1.2 billion treatment developed by University of California. 6 August 2024
Americas
Pharma company argues that affirming lower court’s decision would shrink Orange Book “dramatically” | District court found Teva’s patents do not claim the drug product for which they are listed. 1 August 2024
Americas
Biopharmaceutical company insisted its cancer treatment should be considered a biologic | Panel finds “unfairly reductive” arguments “just don’t work” | FDA correct to reject Ipsen based on faulty scientific expertise. 30 July 2024
Americas
The appointee represents a diverse range of tech clients, including in medtech and life sciences and will now lead the firm’s California offices. 25 July 2024